Farudodstat

Farudodstat (ASLAN003) is an orally active and potent Dihydroorotate Dehydrogenase (DHODH) inhibitor with an IC50 of 35 nM for human DHODH enzyme. Farudodstat inhibits protein synthesis via activation of AP-1 transcription factors. Farudodstat induces apoptosis and substantially prolongs survival in acute myeloid leukemia (AML) xenograft mice[1][2].

Product Specifications

CAS Number

[1035688-66-4]

Product Name Alternative

ASLAN003

UNSPSC

12352005

Hazard Statement

H315, H319, H335

Target

Apoptosis; Dihydroorotate Dehydrogenase; DNA/RNA Synthesis

Type

Reference compound

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/aslan003.html

Concentration

10mM

Purity

99.95

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

O=C(C1=CC=CN=C1NC2=C(F)C=C(C3=CC=CC(OC)=C3)C=C2F)O

Molecular Formula

C19H14F2N2O3

Molecular Weight

356.32

Precautions

H315, H319, H335

References & Citations

[1]Marco L. Lolli, et al. Human Dihydroorotate Dehydrogenase (hDHODH) as a new target on Acute Myelogenous Leukemia (AML) : Targeting Myeloid Differentiation using Potent and Innovative hDHODH Inhibitors. 23rd Swedish Conference on Macromolecular Structure and Function Tällberg, 14-17 June 2019|[2]Jianbiao Zhou, et al. ASLAN003, a potent dihydroorotate dehydrogenase inhibitor for differentiation of acute myeloid leukemia. Haematologica. 2019 Nov7; haematol.2019.230482.